The Role of mTOR Inhibitors in COVID-19 Outcomes Among Heart Transplant Recipients
Viruses · 2025
DOI: 10.3390/v18010029 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Viruses, 2025. Verfasst von Agnieszka Kuczaj und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiac, Vascular and Endovascular Surgery and Transplantology, Faculty of Medical Sciences in Zabrze, Medical University of Silesia in…. Hauptthemen laut MEDLINE: Heart Transplantation, COVID-19, MTOR Inhibitors, Immunosuppressive Agents. Die Arbeit nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Heart failure (HF) remains a major global health challenge, with orthotopic heart transplantation (OHT) serving as the gold-standard therapy for end-stage disease. Chronic immunosuppression required to prevent graft rejection increases the risk of infections and malignancies. The COVID-19 pandemic underscored the particular vulnerability of transplant recipients to severe SARS-CoV-2 infection. Specific immunosuppressive agents used in OHT patients may differentially affect SARS-CoV-2 infection. In particular, mTOR inhibitors may modulate viral replication and immune responses, potentially influencing disease severity.
Objectives
This study evaluated the impact of immunosuppressive regimens—particularly mTOR inhibitors—on COVID-19 outcomes in heart transplant recipients, comparing mTOR-based therapy (with or without calcineurin inhibitors, CNIs) to non-mTOR-based regimens.
Methods
This single-center retrospective observational study included 556 orthotopic heart transplant recipients (76.3% male; median age, 58 years) followed from March 2020 to March 2024. To compare patients receiving mTOR inhibitors with similar non-mTOR recipients, 3:1 propensity score matching was performed based on age, sex, and body mass index. Among the study population, 88 patients (15.8%) received mTOR inhibitors (everolimus or sirolimus), of whom 66 were concomitantly treated with calcineurin inhibitors and 22 without. Data were obtained from the National Health Fund database and clinical follow-ups.
Results
Overall mortality was 13.5%, and COVID-19-related mortality 3.2%. COVID-19 incidence was 33% in the mTOR group versus 36.7% in the non-mTOR group (p = 0.52). Hospitalization rates were 3.4% and 6.4% (p = 0.29), respectively. All-cause mortality was higher among mTOR users (21.6% vs. 11.7%, p = 0.02), especially in the mTOR+CNI subgroup. Notably, no COVID-19-related deaths occurred in the mTOR CNI-free group. Conclusions: mTOR-based immunosuppression was non-inferior to standard therapy for COVID-19 outcomes. The absence of COVID-19-related deaths in patients on mTOR CNI-free regimens suggests potential protective effects that merit further investigation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cardiac, Vascular and Endovascular Surgery and Transplantology, Faculty of Medical Sciences in Zabrze, Medical University of Silesia in Katowice, Silesian Center for Heart Diseases, M.C. Skłodowskiej 9, 41…
- Students' Scientific Association, Faculty of Medical Sciences in Zabrze, Medical University of Silesia in Katowice, M.C. Skłodowskiej 9, 41-800 Zabrze, Poland.
ORCID-Profile: Szymon Warwas, Oliwia Jewuła, Tomasz Hrapkowicz
Zitieren
APA
Kuczaj, A., Warwas, S., Tyrka, M., Skotnicki, B., Szymecki, D., Jewuła, O., Pawlak, S., Przybyłowski, P., & Hrapkowicz, T. (2025). The Role of mTOR Inhibitors in COVID-19 Outcomes Among Heart Transplant Recipients. Viruses. https://doi.org/10.3390/v18010029
Vancouver
Kuczaj A, Warwas S, Tyrka M, Skotnicki B, Szymecki D, Jewuła O, et al. The Role of mTOR Inhibitors in COVID-19 Outcomes Among Heart Transplant Recipients. Viruses. 2025. doi:10.3390/v18010029
BibTeX
@article{Kuczaj2025,
author = {Kuczaj, Agnieszka and Warwas, Szymon and Tyrka, Mikołaj and Skotnicki, Błażej and Szymecki, Daniel and Jewuła, Oliwia and Pawlak, Szymon and Przybyłowski, Piotr and Hrapkowicz, Tomasz},
title = {The Role of mTOR Inhibitors in COVID-19 Outcomes Among Heart Transplant Recipients},
journal = {Viruses},
year = {2025},
doi = {10.3390/v18010029}
}
EUVIMED